Boehringer Ingelheim Wins EU Approval for JASCAYD
INGELHEIM, Germany, July 17, 2026 Boehringer Ingelheim has announced that the European Commission (EC) has granted marketing authorization for...
Pulmonary Fibrosis
Advertisement
Celea Doses First Patient in Phase 3 SURPASS-IPF Trial
BOSTON, July 13, 2026 Celea Therapeutics announced that the first patient has been dosed in the global Phase 3...
Insilico Begins Phase III Trial of AI-Designed IPF Therapy
CAMBRIDGE, Mass., July 7, 2026 Insilico Medicine has announced the initiation of its Phase III clinical trial evaluating Rentosertib,...
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 in IPF
LA JOLLA, Calif., June 18, 2026 GRI Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Boehringer Ingelheim Reports Survival Gains With Nerandomilast
INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...
Advertisements
Rein Therapeutics Expands Phase 2 RENEW Trial into the UK
AUSTIN, Texas, June 11, 2026 Rein Therapeutics, Inc. (NASDAQ: RNTX) announced the expansion of its ongoing Phase 2 RENEW...
Boehringer Ingelheim Strengthens Fibrosis Portfolio With JASCAYD
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that the European Medicines Agency’s Committee for Medicinal Products for...
Oorja Bio Reports Positive Phase 1 Data for ORJ-001 in IPF
HOUSTON, Texas, May 19, 2026 Oorja Bio announced positive first-in-human Phase 1 clinical data for ORJ-001, a first-in-class peptide...
Transpire Bio Gains FDA Acceptance for High-Strength Generic Trelegy
SUNRISE, Fla., May 11, 2026 Transpire Bio Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
Advertisement
